Company Description
Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commerc...
Pfizer Inc. engages in the discovery, development, and manufacture of healthcare products specializes in medicines, vaccine, and consumer healthcare. It operates through the Pfizer Innovative Health (IH) and Pfizer Essential Health (EH) segments. The IH segment focuses on the development and commercializing medicines and vaccines for internal medicine, oncology, inflammation and immunology, rate disease, and consumer healthcare. The EH segment is involved in development and supply of branded generics, generic sterile injectable products, biosimilars, and select branded products including anti-infectives. The company was founded by Charles Pfizer Sr. and Charles Erhart in 1849 and is headquartered in New York, NY.
Valuation
P/E Current
22.02
P/E Ratio (with extraordinary items)
22.14
P/E Ratio (without extraordinary items)
21.56
Price to Sales Ratio
4.95
Price to Book Ratio
3.24
Price to Cash Flow Ratio
14.39
Enterprise Value to EBITDA
17.05
Enterprise Value to Sales
5.65
Total Debt to Enterprise Value
0.17
Efficiency
Revenue/Employee
533,860.00
Income Per Employee
88,981.00
Receivables Turnover
5.03
Total Asset Turnover
0.26
Liquidity
Current Ratio
1.35
Quick Ratio
1.04
Cash Ratio
0.47
Profitability
Gross Margin
71.21
Operating Margin
21.52
Pretax Margin
17.89
Net Margin
16.67
Return on Assets
4.34
Return on Equity
11.05
Return on Total Capital
8.14
Return on Invested Capital
6.93
Capital Structure
Total Debt to Total Equity
65.26
Total Debt to Total Capital
39.49
Total Debt to Total Assets
26.76
Long-Term Debt to Equity
60.48
Long-Term Debt to Total Capital
36.60
Officers and Executives
Name | Age | Officer Since | Title |
---|---|---|---|
Dr. Albert Bourla | 58 | 1993 | Chairman, Chief Executive & Operating Officer |
Mr. Frank A. D'Amelio | 61 | 2007 | Chief Financial Officer & EVP-Business Operations |
Dr. Aida Habtezion | - | - | Chief Medical Officer |
Dr. Mikael Dolsten | 60 | 2009 | President-Bio Therapeutics Research & Development |
Ms. Lidia L. Fonseca | 50 | - | Chief Technology Officer & EVP |
Insider Actions
02/27/2021 |
Frank A. D'Amelio Executive Vice President |
96,872 | Derivative/Non-derivative trans. at $34.64 per share. | 3,355,646 |
02/27/2021 |
Frank A. D'Amelio Executive Vice President |
27,381 | Derivative/Non-derivative trans. at $33.49 per share. | 916,989 |
02/27/2021 |
John D. Young Group President |
82,057 | Derivative/Non-derivative trans. at $34.64 per share. | 2,842,454 |
02/27/2021 |
John D. Young Group President |
23,194 | Derivative/Non-derivative trans. at $33.49 per share. | 776,767 |
02/27/2021 |
Alexander Roderick MacKenzie Executive Vice President |
18,919 | Derivative/Non-derivative trans. at $34.64 per share. | 655,354 |
02/27/2021 |
Alexander Roderick MacKenzie Executive Vice President |
5,812 | Derivative/Non-derivative trans. at $33.49 per share. | 194,643 |
02/27/2021 |
Mikael Dolsten President R&D |
23,841 | Derivative/Non-derivative trans. at $33.49 per share. | 798,435 |
02/27/2021 |
Sally Susman Executive Vice President |
45,587 | Derivative/Non-derivative trans. at $34.64 per share. | 1,579,133 |
02/27/2021 |
Sally Susman Executive Vice President |
14,004 | Derivative/Non-derivative trans. at $33.49 per share. | 468,993 |
02/27/2021 |
Albert Bourla Chairman & CEO; Director |
34,191 | Derivative/Non-derivative trans. at $34.64 per share. | 1,184,376 |
02/27/2021 |
Albert Bourla Chairman & CEO; Director |
9,664 | Derivative/Non-derivative trans. at $33.49 per share. | 323,647 |
02/27/2021 |
Douglas M. Lankler Executive Vice President |
34,191 | Derivative/Non-derivative trans. at $34.64 per share. | 1,184,376 |
02/27/2021 |
Douglas M. Lankler Executive Vice President |
9,664 | Derivative/Non-derivative trans. at $33.49 per share. | 323,647 |
02/27/2021 |
Rady A. Johnson Executive Vice President |
15,955 | Derivative/Non-derivative trans. at $34.64 per share. | 552,681 |
02/27/2021 |
Rady A. Johnson Executive Vice President |
4,510 | Derivative/Non-derivative trans. at $33.49 per share. | 151,039 |
02/27/2021 |
Angela Hwang Group President |
6,268 | Derivative/Non-derivative trans. at $34.64 per share. | 217,123 |
02/27/2021 |
Angela Hwang Group President |
1,772 | Derivative/Non-derivative trans. at $33.49 per share. | 59,344 |
02/27/2021 |
William R. Carapezzi Executive Vice President |
13,676 | Derivative/Non-derivative trans. at $34.64 per share. | 473,736 |
02/27/2021 |
William R. Carapezzi Executive Vice President |
2,985 | Derivative/Non-derivative trans. at $33.49 per share. | 99,967 |
02/27/2021 |
Jennifer B. Damico SVP & Controller |
6,268 | Derivative/Non-derivative trans. at $34.64 per share. | 217,123 |
02/27/2021 |
Jennifer B. Damico SVP & Controller |
1,229 | Derivative/Non-derivative trans. at $33.49 per share. | 41,159 |
02/27/2021 |
Frank A. D'Amelio Executive Vice President |
152,785 | Derivative/Non-derivative trans. at $22.35 per share. | 3,414,744 |
02/27/2021 |
John D. Young Group President |
129,419 | Derivative/Non-derivative trans. at $22.35 per share. | 2,892,514 |
02/27/2021 |
Alexander Roderick MacKenzie Executive Vice President |
29,838 | Derivative/Non-derivative trans. at $22.35 per share. | 666,879 |
02/27/2021 |
Sally Susman Executive Vice President |
71,899 | Derivative/Non-derivative trans. at $22.35 per share. | 1,606,942 |
02/27/2021 |
Albert Bourla Chairman & CEO; Director |
53,925 | Derivative/Non-derivative trans. at $22.35 per share. | 1,205,223 |
02/27/2021 |
Douglas M. Lankler Executive Vice President |
53,925 | Derivative/Non-derivative trans. at $22.35 per share. | 1,205,223 |
02/27/2021 |
Rady A. Johnson Executive Vice President |
25,165 | Derivative/Non-derivative trans. at $22.35 per share. | 562,437 |
02/27/2021 |
Angela Hwang Group President |
9,886 | Derivative/Non-derivative trans. at $22.35 per share. | 220,952 |
02/27/2021 |
William R. Carapezzi Executive Vice President |
21,570 | Derivative/Non-derivative trans. at $22.35 per share. | 482,089 |
02/27/2021 |
Jennifer B. Damico SVP & Controller |
9,886 | Derivative/Non-derivative trans. at $22.35 per share. | 220,952 |
02/25/2021 |
Frank A. D'Amelio Executive Vice President |
105,707 | Derivative/Non-derivative trans. at $34.76 per share. | 3,674,375 |
02/25/2021 |
Frank A. D'Amelio Executive Vice President |
28,221 | Derivative/Non-derivative trans. at $33.82 per share. | 954,434 |
02/25/2021 |
John D. Young Group President |
105,707 | Derivative/Non-derivative trans. at $34.76 per share. | 3,674,375 |
02/25/2021 |
John D. Young Group President |
28,221 | Derivative/Non-derivative trans. at $33.82 per share. | 954,434 |
02/25/2021 |
Alexander Roderick MacKenzie Executive Vice President |
14,227 | Derivative/Non-derivative trans. at $33.82 per share. | 481,157 |
02/25/2021 |
Mikael Dolsten President R&D |
28,271 | Derivative/Non-derivative trans. at $33.82 per share. | 956,125 |
02/25/2021 |
Mikael Dolsten President R&D |
28,271 | Derivative/Non-derivative trans. at $33.82 per share. | 956,125 |
02/25/2021 |
Sally Susman Executive Vice President |
52,853 | Derivative/Non-derivative trans. at $34.76 per share. | 1,837,170 |
02/25/2021 |
Sally Susman Executive Vice President |
15,335 | Derivative/Non-derivative trans. at $33.82 per share. | 518,629 |
02/25/2021 |
Albert Bourla Chairman & CEO; Director |
105,707 | Derivative/Non-derivative trans. at $34.76 per share. | 3,674,375 |
02/25/2021 |
Albert Bourla Chairman & CEO; Director |
28,221 | Derivative/Non-derivative trans. at $33.82 per share. | 954,434 |
02/25/2021 |
Douglas M. Lankler Executive Vice President |
64,599 | Derivative/Non-derivative trans. at $34.76 per share. | 2,245,461 |
02/25/2021 |
Douglas M. Lankler Executive Vice President |
17,246 | Derivative/Non-derivative trans. at $33.82 per share. | 583,259 |
02/25/2021 |
Rady A. Johnson Executive Vice President |
24,371 | Derivative/Non-derivative trans. at $34.76 per share. | 847,135 |
02/25/2021 |
Rady A. Johnson Executive Vice President |
6,422 | Derivative/Non-derivative trans. at $33.82 per share. | 217,192 |
02/25/2021 |
Angela Hwang Group President |
14,682 | Derivative/Non-derivative trans. at $34.76 per share. | 510,346 |
02/25/2021 |
Angela Hwang Group President |
3,920 | Derivative/Non-derivative trans. at $33.82 per share. | 132,574 |
02/25/2021 |
William R. Carapezzi Executive Vice President |
17,618 | Derivative/Non-derivative trans. at $34.76 per share. | 612,401 |
02/25/2021 |
William R. Carapezzi Executive Vice President |
2,983 | Derivative/Non-derivative trans. at $33.82 per share. | 100,885 |
02/25/2021 |
Payal Sahni Executive Vice President |
6,460 | Derivative/Non-derivative trans. at $34.76 per share. | 224,549 |
02/25/2021 |
Payal Sahni Executive Vice President |
1,197 | Derivative/Non-derivative trans. at $33.82 per share. | 40,482 |
02/25/2021 |
Jennifer B. Damico SVP & Controller |
8,075 | Derivative/Non-derivative trans. at $34.76 per share. | 280,687 |
02/25/2021 |
Jennifer B. Damico SVP & Controller |
1,496 | Derivative/Non-derivative trans. at $33.82 per share. | 50,594 |
02/25/2021 |
Frank A. D'Amelio Executive Vice President |
163,334 | Derivative/Non-derivative trans. at $22.89 per share. | 3,738,715 |
02/25/2021 |
John D. Young Group President |
163,334 | Derivative/Non-derivative trans. at $22.89 per share. | 3,738,715 |
02/25/2021 |
Sally Susman Executive Vice President |
81,667 | Derivative/Non-derivative trans. at $22.89 per share. | 1,869,357 |
02/25/2021 |
Albert Bourla Chairman & CEO; Director |
163,334 | Derivative/Non-derivative trans. at $22.86 per share. | 3,733,815 |
02/25/2021 |
Douglas M. Lankler Executive Vice President |
99,816 | Derivative/Non-derivative trans. at $22.89 per share. | 2,284,788 |
02/25/2021 |
Rady A. Johnson Executive Vice President |
37,658 | Derivative/Non-derivative trans. at $22.89 per share. | 861,991 |
02/25/2021 |
Angela Hwang Group President |
22,686 | Derivative/Non-derivative trans. at $22.89 per share. | 519,282 |
02/25/2021 |
William R. Carapezzi Executive Vice President |
27,222 | Derivative/Non-derivative trans. at $22.89 per share. | 623,111 |
02/25/2021 |
Payal Sahni Executive Vice President |
9,982 | Derivative/Non-derivative trans. at $22.89 per share. | 228,487 |
02/25/2021 |
Jennifer B. Damico SVP & Controller |
12,477 | Derivative/Non-derivative trans. at $22.89 per share. | 285,598 |
02/25/2021 |
Alexander Roderick MacKenzie Executive Vice President |
26,732 | Award at $0 per share. | 0 |
02/25/2021 |
Jennifer B. Damico SVP & Controller |
3,649 | Award at $0 per share. | 0 |
02/22/2021 |
William R. Carapezzi Executive Vice President |
1,410 | Derivative/Non-derivative trans. at $34.26 per share. | 48,306 |
02/22/2021 |
Payal Sahni Executive Vice President |
1,172 | Derivative/Non-derivative trans. at $34.26 per share. | 40,152 |
02/22/2021 |
Jennifer B. Damico SVP & Controller |
884 | Derivative/Non-derivative trans. at $34.26 per share. | 30,285 |
01/31/2021 |
Lidia L. Fonseca Executive Vice President |
6,749 | Derivative/Non-derivative trans. at $35.9 per share. | 242,289 |
12/29/2020 |
John D. Young Group President |
10,607 | Derivative/Non-derivative trans. at $37.05 per share. | 392,989 |
12/16/2020 |
Rady A. Johnson Executive Vice President |
661 | Gift at $0 per share. | 0 |
12/16/2020 |
Angela Hwang Group President |
12,970 | 490,784 | |
11/09/2020 |
Sally Susman Executive Vice President |
43,662 | Disposition at $41.94 per share. | 1,831,184 |
11/09/2020 |
Albert Bourla Chairman & CEO; Director |
132,508 | Disposition at $41.94 per share. | 5,557,385 |
08/06/2020 |
Ronald E. Blaylock Director |
1,000 | Acquisition at $38.62 per share. | 38,620 |
08/06/2020 |
Ronald E. Blaylock Director |
1,000 | Acquisition at $38.69 per share. | 38,690 |
08/06/2020 |
Ronald E. Blaylock Director |
1,500 | Acquisition at $38.51 per share. | 57,765 |
08/06/2020 |
Ronald E. Blaylock Director |
2,500 | Acquisition at $38.56 per share. | 96,400 |
08/06/2020 |
Ronald E. Blaylock Director |
3,000 | Acquisition at $38.55 per share. | 115,650 |
08/06/2020 |
Ronald E. Blaylock Director |
4,000 | Acquisition at $38.49 per share. | 153,960 |
06/05/2020 |
Jennifer B. Damico SVP & Controller |
2,181 | Disposition at $36.13 per share. | 78,799 |
05/18/2020 |
Mikael Dolsten President R&D |
24,242 | Disposition at $37.79 per share. | 916,105 |
05/18/2020 |
Mikael Dolsten President R&D |
17,357 | Disposition at $37.78 per share. | 655,747 |
05/18/2020 |
Mikael Dolsten President R&D |
16,840 | Disposition at $37.8 per share. | 636,552 |
05/18/2020 |
Mikael Dolsten President R&D |
14,727 | Disposition at $37.77 per share. | 556,238 |
05/18/2020 |
Mikael Dolsten President R&D |
9,700 | Disposition at $37.75 per share. | 366,175 |
05/18/2020 |
Mikael Dolsten President R&D |
6,470 | Disposition at $37.81 per share. | 244,630 |
05/18/2020 |
Mikael Dolsten President R&D |
5,517 | Disposition at $37.76 per share. | 208,321 |
05/18/2020 |
Mikael Dolsten President R&D |
500 | Disposition at $37.82 per share. | 18,910 |
MarketWatch News on PFE
-
Johnson & Johnson stock underperforms Monday when compared to competitors despite daily gains
- MarketWatch Automation
-
How Biogen Stock Could Rise 85%. Two Drugs Are Critical.
- Josh Nathan-Kazis
-
J&J’s Vaccine Pause Could Have Ripple Effects for the World
- Josh Nathan-Kazis
-
Half of all adults in U.S. have received at least one COVID-19 shot
- Associated Press
- Loading more headlines...
Other News on PFE
-
Ocugen’s Outlook Is Still Very Bleak
- InvestorPlace.com
-
J&J’s Covid-19 Vaccine Adds $100 Million to Quarterly Sales
- Peter Loftus
-
China set to approve BioNTech vaccine in June - Bloomberg
- Seeking Alpha
-
Is It Too Late to Buy Moderna After Its 40% Gain?
- Motley Fool
-
A Covid-19 Lesson From Countries With Rapid Vaccine Rollouts
- Jason Douglas
-
I Got My Jab, Here's What Happened, And A Look At Vaccine Stocks
- Seeking Alpha
-
What Does J&J's Pause Mean for Investors?
- Motley Fool
-
2 REITs That Could Double In The Recovery
- Seeking Alpha
-
Wall Street Breakfast: Rev Up The Earnings
- Seeking Alpha
-
Post Covid-19, Don’t Forget About Healthcare Stocks
- Charley Grant
-
What Is Covax and How Will It Deliver Covid-19 Vaccines to Poorer Countries?
- Gabriele Steinhauser
-
Pfizer (PFE) Gets a Buy Rating from Mizuho Securities
- SmarterAnalyst
- Loading more headlines...